Use of dexmedetomidine in critical-ill patients: is it time to look to the actual evidence?

© The Author(s) 2023. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecom‐ mons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. Critical Care

To the editor Dexmedetomidine is an alpha-2 (ɑ2) adrenergic receptor and imidazoline type 2 receptor agonist that received Food and Drug Administration (FDA) approval in 1999 as a sedative and analgesic that also reduces stress, anxiety, and the risk of delirium in critically ill patients.Commercialized under the name Precedex by Pfizer, it has been used widely across the globe, and it´s still considered to be part of a gold-standard care agent alongside propofol for critically ill patients, patients in the operating room and patients under mechanical ventilation [1].However, robust evidence published in the last years show serious concerns about its safety and efficacy as a sedative agent, leading to the debate about its recommended usage.
The SPICE III was a randomized controlled trial that included 4000 patients and evaluated the mortality at the ICU when administering dexmedetomidine at a maximum dose of 1.5 mcg/kg/h adjusted to reach a targeted Richmond Agitation and Sedation Scale (RASS) score of − 2 to + 1, compared to usual care involving propofol and benzodiazepines [2].The study reported no significant difference in 90-day mortality (95% CI − 2.9 to 2.8, p = 0.98).However, trying to reach the targeted RASS score, the dexmedetomidine group needed more sedative agents when compared with the control group, reflecting a potential and considerable efficacy issue of the agent.Added to this, the dexmedetomidine group experienced a significantly higher incidence of adverse effects including bradycardia (5.1% vs. 0.5%, p = < 0.0001), hypotension (2.7% vs. 0.5%, p = < 0.0001), and persistent asystole (0.7% vs. 0.1%, p = 0.003), indicating a potential major flaw of the indiscriminate use of dexmedetomidine.A subgroup analysis revealed varied treatment responses based on age, with a significant higher mortality observed in patients younger than 63.7 years.Although exploratory results from subgroup analysis should be taken cautiously, this might represent the opening of an unprecedented and unexpected pandora box in one of the most common sedative strategies worldwide.
Consequently, a post-hoc Bayesian analysis that included 3905 ventilated critical ill patients confirmed the subgroup analysis results [3].The analysis suggested that the utilization of dexmedetomidine may have a higher probability of 90-day mortality in patients aged ≤ 65 years (OR 1.26, 95% CI 1.02-1.56)with a 98.5% probability of harm when compared to usual care sedation.
Added to this, another sub-analysis of SPICE III explored the association between different infusion doses of dexmedetomidine and propofol, as well as their relationship with mortality, with consideration for age [4].The findings indicated that increasing the dexmedetomidine dose was associated with elevated 90-day mortality in younger (age < 65 years) patients (HR 1.3, 95% CI 1.03-1.65,p = 0.029).
Although dexmedetomidine showed promise as a sedative, there are current concerns that should not be overlooked regarding its use.Figure 1 illustrates the timeline of relevant events related to the use of dexmedetomidine in critically ill patients.The results of SPICE III even led to the issuance of a health alert in Europe (https:// www.ema.europa.eu/ en/ medic ines/ dhpc/ dexme detom idine-incre ased-risk-morta lity-inten sive-care-unit-icu-patie nts-65-years.)and New Zealand (https:// www.medsa fe.govt.nz/ safety/ DHCPL etters/ Dexme detom idine Febrr uary2 023.pdf.) about the risks of using dexmedetomidine.The commercialization of dexmedetomidine represents a millionaire market for the pharmaceutical industry and this should not overshadow the current evidence regarding its efficacy and safety.Still, further studies are needed to determine if dexmedetomidine can still be recommended in particular scenarios and in definitive, task force groups are needed to take action based on the currently published data.• support for research data, including large and complex data types • gold Open Access which fosters wider collaboration and increased citations maximum visibility for your research: over 100M website views per year

•
At BMC, research is always in progress.

Learn more biomedcentral.com/submissions
Ready to submit your research Ready to submit your research ?Choose BMC and benefit from: ? Choose BMC and benefit from:

Fig.
Fig. Timeline of key milestones in the use of dexmedetomidine in critically Ill patients